Stocks and Investing
Stocks and Investing
Tue, August 2, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Nathan Rich Maintained (TEVA) at Hold with Increased Target to $10 on, Aug 2nd, 2022
Nathan Rich of Goldman Sachs, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Increased Target from $9 to $10 on, Aug 2nd, 2022.
Nathan has made no other calls on TEVA in the last 4 months.
There are 4 other peers that have a rating on TEVA. Out of the 4 peers that are also analyzing TEVA, 2 agree with Nathan's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Ashwani Verma of "UBS" Initiated at Hold and Held Target at $10 on, Tuesday, June 14th, 2022
- Jason Gerberry of "B of A Securities" Upgraded from Sell to Hold and Held Target at $9 on, Tuesday, May 17th, 2022
These are the ratings of the 2 analyists that currently disagree with Nathan
- David Amsellem of "Piper Sandler" Downgraded from Hold to Sell and Decreased Target to $7 on, Wednesday, May 4th, 2022
- Balaji Prasad of "Barclays" Upgraded from Hold to Buy and Increased Target to $13 on, Tuesday, April 5th, 2022
Contributing Sources